2011
DOI: 10.1016/j.anai.2011.06.008
|View full text |Cite
|
Sign up to set email alerts
|

Utility of routine laboratory testing in management of chronic urticaria/angioedema

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
9
0
1

Year Published

2012
2012
2020
2020

Publication Types

Select...
6
4

Relationship

0
10

Authors

Journals

citations
Cited by 37 publications
(10 citation statements)
references
References 14 publications
0
9
0
1
Order By: Relevance
“…Of 285 patients treated with thyroid medication, CSU was improved in 120 (42%) patients. Fourteen studies reported complete remission of CSU in 68 patients (24%) and partial improvement in 28 patients (10%) . Beneficial effects were not specified in 24 (8%) of 285 patients in two studies and were not seen in six studies in all patients.…”
Section: Resultsmentioning
confidence: 98%
“…Of 285 patients treated with thyroid medication, CSU was improved in 120 (42%) patients. Fourteen studies reported complete remission of CSU in 68 patients (24%) and partial improvement in 28 patients (10%) . Beneficial effects were not specified in 24 (8%) of 285 patients in two studies and were not seen in six studies in all patients.…”
Section: Resultsmentioning
confidence: 98%
“…In another recent study, Tarbox et al evaluated the utility of routine laboratory testing in CIU and concluded that such testing rarely leads to changes in management or better overall outcomes. [29] While this study was well powered with 356 patients, most of the patients had very mild disease as only 61 patients (17%) were taking medications other than antihistamines with or without LTRA. There was no indication of whether the patients were controlled on their medication regimen.…”
Section: Discussionmentioning
confidence: 99%
“…52 Evidence suggests that laboratory testing can be postponed or deferred in most patients with chronic spontaneous urticaria. 53,54 Patients with refractory urticaria could be considered for telehealth or a face-to-face visit to recommend further evaluation and management, including initiation of omalizumab in properly selected patients. 55…”
Section: Communication With Patientsmentioning
confidence: 99%